HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.
The Company’s presentation is scheduled for 2:45-3:20 PM ET on June 12th. The Company will also host one-on-one investor meetings throughout the day. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website at https://investor.harvardbioscience.com. A replay will be available shortly after the presentation has concluded. To schedule a one-on-one meeting, please contact the Three Part Advisors conference team at (817) 769-2373 or This email address is being protected from spambots. You need JavaScript enabled to view it..
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Harvard Bioscience
Jennifer Cote, Chief Financial Officer
(508) 893-3120
Investor Contacts:
Three Part Advisors
Sandy Martin / Erol Girgin / William Shelmire
This email address is being protected from spambots. You need JavaScript enabled to view it.
(214) 616-2207
Last Trade: | US$2.11 |
Daily Change: | 0.01 0.48 |
Daily Volume: | 278,332 |
Market Cap: | US$92.040M |
November 07, 2024 October 03, 2024 September 18, 2024 May 23, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB